Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection.
TURCO, R. *; MARTINELLI, M. *; MIELE, E. *; ROSCETTO, E. +; DEL PEZZO, M. +; GRECO, L. *; STAIANO, A. *
[Article] Alimentary Pharmacology & Therapeutics. 31(7):754-759, April 1, 2010.

(Format: HTML, PDF)

Background: Proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) may play an important role on the onset of Clostridium difficile-associated disease (CDAD) in adults. The impact of Clostridium difficile on children treated with gastric acid-suppressing agents remains unknown.

Aim: To investigate the relationship between CDAD and exposure to acid suppressive therapy in hospitalized paediatric patients.

Methods: We reviewed the medical records of children, with a diagnosis of protracted diarrhoea and abdominal pain, whose stool was analysed for C. difficile toxins. We identified 68 patients with CDAD. For each patient, we randomly selected one control subjects with stool analysis negative for C. difficile. Comorbid illnesses, previous hospitalizations, antibiotics, corticosteroids, immunosuppressants and gastric acid suppressing exposures were recorded.

Results: The use of PPI was significantly higher in C. difficile positive group compared with C. difficile negative group [odds ratio (OR): = 4.5; 95% confidence interval (CI) = 1.4-14.4]. We also found a trend for the use of H2RAs in patients infected by C. difficile compared with C. difficile negative comparison group (OR: = 3.8; 95% CI = 0.7-18.9).

Conclusions: Children exposed to PPIs therapy seem to be at higher risk for the development of Clostridium difficile-associated disease.

Copyright (C) 2010 Blackwell Publishing Ltd.